trending Market Intelligence /marketintelligence/en/news-insights/trending/v_KrETzkJ03GcKLlPke6gg2 content esgSubNav
In This List

Sinopharm Group FY'18 profit up 4.7% YOY

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Sinopharm Group FY'18 profit up 4.7% YOY

Shanghai-based Sinopharm Group Co. Ltd.'s profit for full year 2018 grew 4.7% year over year.

Profit attributable to equity holders of the parent reached 5.84 billion yuan, from 5.58 billion yuan in 2017.

Diluted EPS was 1.97 yuan, compared to 1.88 yuan a year earlier.

Revenue for the year ended Dec. 31, 2018, grew 11.7% to 344.53 billion yuan, from 308.35 billion in 2017.

Revenue from the company's pharmaceutical distribution segment, which represents 80.4% of the group's total revenue, grew 9.3% to 281.05 billion.

Sinopharm, a wholesaler and retailer of pharmaceutical and healthcare products, booked 2018 operating profit of 15.40 billion yuan, from 13.14 billion a year earlier.

As of March 22, US$1 was equivalent to 6.72 Chinese yuan.